EA200200246A1 - Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки - Google Patents

Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки

Info

Publication number
EA200200246A1
EA200200246A1 EA200200246A EA200200246A EA200200246A1 EA 200200246 A1 EA200200246 A1 EA 200200246A1 EA 200200246 A EA200200246 A EA 200200246A EA 200200246 A EA200200246 A EA 200200246A EA 200200246 A1 EA200200246 A1 EA 200200246A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nsaid
kinase inhibitor
polypes
columna
colum
Prior art date
Application number
EA200200246A
Other languages
English (en)
Other versions
EA006876B1 (ru
Inventor
Филип Фрост
Каролин Мари Дискафани-Марро
Original Assignee
Американ Цианамид Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Цианамид Компани filed Critical Американ Цианамид Компани
Publication of EA200200246A1 publication Critical patent/EA200200246A1/ru
Publication of EA006876B1 publication Critical patent/EA006876B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способу лечения и ингибирования полипов в ободочной кишке или рака ободочной и прямой кишки у нуждающегося в этом млекопитающего, который включает введение указанному млекопитающему средства нестероидной противовоспалительной терапии (NSAID) и ингибитора киназы рецептора эпидермального фактора роста (EGFR).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200246A 1999-08-12 2000-08-02 Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки EA006876B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
EA200200246A1 true EA200200246A1 (ru) 2002-08-29
EA006876B1 EA006876B1 (ru) 2006-04-28

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200246A EA006876B1 (ru) 1999-08-12 2000-08-02 Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки

Country Status (24)

Country Link
EP (1) EP1202746B1 (ru)
JP (1) JP2003507342A (ru)
KR (1) KR20020018201A (ru)
CN (1) CN1229142C (ru)
AR (1) AR029763A1 (ru)
AT (1) ATE341341T1 (ru)
AU (1) AU783116B2 (ru)
BR (1) BR0013219A (ru)
CA (1) CA2380904C (ru)
CZ (1) CZ2002474A3 (ru)
DE (1) DE60031127T2 (ru)
DK (1) DK1202746T3 (ru)
EA (1) EA006876B1 (ru)
ES (1) ES2272305T3 (ru)
HK (1) HK1042244A1 (ru)
HU (1) HUP0203162A3 (ru)
IL (1) IL147913A0 (ru)
MX (1) MXPA02001448A (ru)
NO (1) NO20020663L (ru)
NZ (1) NZ517120A (ru)
PL (1) PL353267A1 (ru)
PT (1) PT1202746E (ru)
WO (1) WO2001012227A1 (ru)
ZA (1) ZA200201156B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
JP2005506366A (ja) * 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
DE60318089T2 (de) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
EP1570080A4 (en) * 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
NZ551431A (en) 2004-06-03 2010-04-30 Hoffmann La Roche Treatment with cisplatin and an EGFR-inhibitor
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
PL2245026T3 (pl) 2008-02-07 2013-01-31 Boehringer Ingelheim Int Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) * 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
AU2012262014B2 (en) * 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200000488A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
PL340800A1 (en) * 1997-11-06 2001-02-26 American Cyanamid Co Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps

Also Published As

Publication number Publication date
MXPA02001448A (es) 2002-07-02
PL353267A1 (en) 2003-11-03
IL147913A0 (en) 2002-08-14
AU6395900A (en) 2001-03-13
ES2272305T3 (es) 2007-05-01
AR029763A1 (es) 2003-07-16
ZA200201156B (en) 2003-05-12
ATE341341T1 (de) 2006-10-15
EP1202746B1 (en) 2006-10-04
JP2003507342A (ja) 2003-02-25
DK1202746T3 (da) 2007-01-02
HUP0203162A3 (en) 2006-07-28
CN1370080A (zh) 2002-09-18
CA2380904C (en) 2009-02-10
EP1202746A1 (en) 2002-05-08
PT1202746E (pt) 2007-01-31
DE60031127D1 (de) 2006-11-16
KR20020018201A (ko) 2002-03-07
EA006876B1 (ru) 2006-04-28
WO2001012227A1 (en) 2001-02-22
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
HK1042244A1 (zh) 2002-08-09
NO20020663D0 (no) 2002-02-11
CN1229142C (zh) 2005-11-30
NZ517120A (en) 2004-10-29
HUP0203162A2 (hu) 2003-01-28
DE60031127T2 (de) 2007-02-01
NO20020663L (no) 2002-04-09
BR0013219A (pt) 2002-04-23
CZ2002474A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
EA200200246A1 (ru) Композиция, содержащая нестероидное противовоспалительное средство (nsaid) и ингибитор киназы egfr, для лечения или ингибирования полипов в ободочной кишке и рака ободочной и прямой кишки
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
NO20052055L (no) Sammensetninger og fremgangsmater for behandling av prostata- og andre cancere
ATE283700T1 (de) Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EA200300306A1 (ru) Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
BR9805544A (pt) Uso de um composto.
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
NO20033883D0 (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
CY1108045T1 (el) Συνδυασμοι που περιλαμβανουν εναν επιλεκτο αναστολεα της κυκλοοξυγενασης-2
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
DE69607615T2 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE361075T1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DK1443942T3 (da) Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM